New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation

References

• Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 379(9816), 648–661 (2012).
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2), 119–125 (2006).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• White RH, McBurnie MA, Manolio T et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am. J. Med. 106(2), 165–171 (1999).
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med. 123(7), 638–645.e4 (2010).
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb. Haemost. 106(5), 968–977 (2011).
   PubMed Web of Science ®Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb. Haemost. 104(1), 49–60 (2010).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113(5), 359–364 (2002).
   PubMed Web of Science ®Google Scholar
• Fang MC, Singer DE, Chang Y et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 112(12), 1687–1691 (2005).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30(6), 1223–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290(8), 1049–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Wenger NK, Feyzi J et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur. Heart J. 27(16), 1947–1953 (2006).
   PubMed Web of Science ®Google Scholar
• Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 307(18), 1952–1958 (2012).
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182, 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur. Heart J. 33(12), 1500–1510 (2012).
   PubMed Web of Science ®Google Scholar
• Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation: a common but neglected entity. Arch. Intern. Med. 156(4), 362–367 (1996).
   Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 84, 527–539 (1991).
   PubMed Web of Science ®Google Scholar
• Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323, 1505–1511 (1990).
   PubMed Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch. Intern. Med. 154, 1449 (1994).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 35(1), 183–187 (2000).
   PubMed Web of Science ®Google Scholar
• Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am. J. Cardiol. 63(5), 366–367 (1989).
   PubMed Web of Science ®Google Scholar
• Seidl K, Hauer B, Schwick NG, Zellner D, Zahn R, Senges J. Risk of thromboembolic events in patients with atrial flutter. Am. J. Cardiol. 82(5), 580–583 (1998).
   PubMedGoogle Scholar
• Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290, 1049–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69, 546–554 (2007).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110(9), 1042–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med. 158, 1316–1320 (1998).
   PubMed Web of Science ®Google Scholar
• American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114, e257–e354 (2006).
   Google Scholar
• Pullicino P, Homma S. Stroke in heart failure: atrial fibrillation revisited? J. Stroke Cerebrovasc. Dis. 19(1), 1–2 (2010).
   Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thrombo­embolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J. Stroke. Cerebrovasc. Dis. 5, 147–157 (1995).
   PubMedGoogle Scholar
• Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol. 110(3), 453–460 (2012).
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107(3), 584–589 (2012).
   PubMed Web of Science ®Google Scholar
• Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation–semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing 33(6), 608–611 (2004).
   Google Scholar
• You JJ, Singer DE, Howard PA et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), e531S–e575S (2012).
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA et al.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123(10), 1144–1150 (2011).
   PubMed Web of Science ®Google Scholar
• Skanes AC, Healey JS, Cairns JA et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28(2), 125–136 (2012).
   PubMed Web of Science ®Google Scholar
• Ogawa S, Hori M. Urgent statement on antithrombotic therapy of atrial fibrillation. Circ. J. 75(12), 2719–2721 (2011).
   Google Scholar
• Camm AJ, Lip GY, De Caterina R et al.; Authors/Task Force Members. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33(21):2719-2747(2012).
   Google Scholar
• Lip GY, Andreotti F, Fauchier L et al.; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb. Haemost. 106(6), 997–1011 (2011).
   PubMed Web of Science ®Google Scholar
• Pengo V, Crippa L, Falanga A et al.; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb. Haemost. 106(5), 868–876 (2011).
   PubMed Web of Science ®Google Scholar
• Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb. Haemost. 107(5), 838–847 (2012).
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103(6), 1116–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Faxon DP, Eikelboom JW, Berger PB et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb. Haemost. 106(4), 572–584 (2011).
   PubMed Web of Science ®Google Scholar
• Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb. Haemost. 106(4), 569–571 (2011).
   PubMed Web of Science ®Google Scholar
• Flaker G, Ezekowitz M, Yusuf S et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J. Am. Coll. Cardiol. 59(9), 854–855 (2012).
   PubMed Web of Science ®Google Scholar
• Ferreira J, Ezekowitz MD, Connolly SJ et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Circulation 124, A10956 (2011).
   Google Scholar